MIRA's Mira-55 Shows Promising Results as Non-Opioid Pain Reliever

MIRA Pharmaceuticals has announced significant preclinical findings for its proprietary compound, Mira-55. This non-psychotropic marijuana analog demonstrated pain relief comparable to morphine in an inflammatory pain model without causing potential opioid-related risks. Unlike THC, Mira-55 selectively activates CB2 cannabinoid receptors, minimizing undesirable effects like euphoria and sedation. As such, it emerges as a potent alternative in large, underserved pain markets.

Studies using the formalin model revealed that Mira-55 effectively reduced pain sensitivity without sedation or inflammation, outcomes traditionally achieved with opioids such as morphine. Additionally, the U.S. Drug Enforcement Administration's classification of Mira-55 as a non-controlled substance bolsters its clinical and commercial prospects.

Strategically, Mira-55 complements MIRA’s existing pipeline asset, Ketamir-2, broadening the company’s non-opioid approach to managing chronic pain disorders. Together, these compounds present diverse mechanisms for addressing inflammatory and neuropathic pain.